Artikkelit - Selaus asiasanan mukaan "Neoplastic disorders"

Viitteet 1-1 / 1

Are products with an orphan designation for oncology indications different from products for other rare indications? : A retrospective analysis of European orphan designations granted between 2002-2012

Pauwels, K.; Huys, I.; Casteels, M.; Larsson, K.; Voltz, C.; Penttilä, Karri; Morel, T.; Simoens, S.
Orphannet Journal of Rare Disease : 1 (BioMed Central, 16.02.2017)

Background: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare ...